These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17079475)

  • 1. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
    Verma A; Wang H; Manavathi B; Fok JY; Mann AP; Kumar R; Mehta K
    Cancer Res; 2006 Nov; 66(21):10525-33. PubMed ID: 17079475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
    Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
    Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
    Fok JY; Mehta K
    Apoptosis; 2007 Aug; 12(8):1455-63. PubMed ID: 17440814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.
    Verma A; Guha S; Diagaradjane P; Kunnumakkara AB; Sanguino AM; Lopez-Berestein G; Sood AK; Aggarwal BB; Krishnan S; Gelovani JG; Mehta K
    Clin Cancer Res; 2008 Apr; 14(8):2476-83. PubMed ID: 18413840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
    Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
    PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
    Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
    Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
    Pham NA; Tsao MS; Cao P; Hedley DW
    Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
    Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
    Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
    Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
    Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
    Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
    Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
    Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
    Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.